Back to Awarded Treatment Trials
Awarded Trial: 98-RC-325B-1
Grant ID
98-RC-325B-1
Illness
Bipolar Disorder
Primary Drug/Intervention
Risperidone
Primary Dosage
up to 2 mg/day
Secondary Drug Intervention
Olanzapine
Secondary Dosage
up to 10 mg/day
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Biederman
Sample Size
31
Duration of Study Period for Each Subject
8 weeks
Outcome Measurements
YMRS
Results
Thirty-one children, aged 4-6 years, were treated with olazapine or risperidone for bipolar disoder. Both drugs improved YMRS scores to a similar degree. Olazapine treatment was associated with a slower rate of improvement, a greater degree of weight gain, and a higher drop-out rate.
Publication
Biederman J, Mick E, Hammerness P, Harpold T, Aleardi M, Dougherty M, Wozniak J. Open-label, 8-week trial of olazapine and risperidone for the treatment of bipolar disoder in preschool-age children. Biol Psychiatry 58: 589-594, 2005.
Link
http://www.ncbi.nlm.nih.gov/pubmed/16239162
PI Name
Joseph Biederman
Degree
MD
Center
ADHD Program
Institution
Massachusetts General Hospital
Address
185 Alewife Brook Parkway, Suite 200
City or Town
Cambridge
State or Province
MA
Zip or Postal Code
2114
Country
USA
Email Address
biederman@helix.mgh.harvard.edu